The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide

Background Natalizumab (NTZ) is a highly effective disease modifying treatment for relapsing multiple sclerosis (RMS), but it increases risk of progressive multifocal leukoencephalopathy (PML) in patients with serum anti- John Cunningham virus (JCV) antibodies. Objective To assess the safety and eff...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Stanley Cohan, Tiffany Gervasi-Follmar, Aneesh Kamath, Vineetha Kamath, Chiayi Chen, Kyle Smoot, Elizabeth Baraban, Keith Edwards
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SAGE Publishing 2021-10-01
coleção:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Acesso em linha:	https://doi.org/10.1177/20552173211066588
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!